Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Tasman Therapeutics, Inc. (Tasman) has announced plans to raise $175 million in Series A funding to support the late-stage clinical development and eventual commercialization of R-107. This innovative ...

The company was also facing challenges in expanding the dose range for alisertib without ... including a Phase I trial with Enhertu and two Phase II trials for alisertib – a novel aurora A ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

In the experimental arms, patients were randomised to receive a 1500mg fixed dose of Imfinzi with or without Imjudo 75mg ... and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan ...

like AstraZeneca's Enhertu (trastuzumab deruxtecan), which required treatment discontinuation. There were nine deaths across the two dose groups, with one deemed treatment-related (in the 12 mg/kg ...

The first two toddlers treated in the dose escalation trial of SENS-501 ... celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to ...

Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If ...